Receptor.AI Partners with Oragenics to Accelerate AI-Guided Discovery of Neurological Therapeutics
Receptor.AI has partnered with Oragenics to enhance the discovery of neurological therapeutics using AI technology. The collaboration will utilize Receptor.AI's AI platform to analyze molecules from Oragenics and generate hypotheses on receptor binding profiles for disorders like Alzheimer's and PTSD. The partnership aims to improve early-stage discovery efficiency through structure-based predictions and extensive profiling of compounds. Both companies believe this collaboration will streamline resources and accelerate the identification of new treatments for neuropsychiatric conditions.
Receptor.AI, a technology-driven drug discovery company, today announced a collaboration with Oragenics, Inc., a clinical-stage biopharmaceutical company, to accelerate the discovery of potential therapeutic candidates for neurological disorders.
Under the collaboration, Receptor.AI will apply its proprietary AI platform to analyze molecules acquired by Oragenics in late 2023 and generate data-driven hypotheses on receptor binding profiles relevant to neurological disorders such as Alzheimer’s disease, dementia, PTSD, and anxiety. The partnership aims to enhance the efficiency of early-stage discovery by providing structure-based predictions of compound–target interactions to guide focused laboratory validation.
Receptor.AI will leverage its advanced AI platform with the goal of accelerating discovery for Oragenics’s CNS programs. The collaboration will combine an LLM–based target profiling with proteome-wide drug–target interaction (DTI) screening across more than 9,000 human proteins. Receptor.AI anticipates it will then retrain a project-specific DTI model fine-tuned to the unique chemical and biological space of Oragenics’s assets.
It is further anticipated that predicted top-ranked interactions will be further analyzed using Receptor.AI’s proprietary ArtiDock AI docking engine, LLM-based pocket identification, and induced-fit docking workflows to reveal likely binding modes and molecular interactions. Each compound will also undergo extensive profiling across more than 60 ADME-Tox, physicochemical, and drug-likeness parameters, ensuring that the most promising candidates are prioritized for experimental validation.
“Early discovery benefits when AI narrows the option space with transparent, testable outputs,” said Dr. Alan Nafiev, CEO of Receptor.AI. “We will deliver ranked targets and binding-mode hypotheses to help Oragenics focus resources on the most promising avenues—anchoring every decision in subsequent experimental data.”
“By leveraging the technology at Receptor.AI to guide our preclinical work, we believe we can focus resources on the most promising opportunities and potentially accelerate our path to identifying new treatments for a wide range of neuropsychiatric conditions,” said Janet Huffman, CEO of Oragenics.
